期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

辅助内分泌治疗在前列腺癌治疗中的应用 被引量：2

下载PDF
导出
摘要 前列腺癌（prostate cancer，PCa）在欧美国家高发，是最常见的男性恶性肿瘤之一，尤其在美国和北欧，在全球范围内，PCa位居男性恶性肿瘤发病率的第二位，仅次于肺癌。PCa在不同种族和国家的发病率相差较大。我国属于PCa的低发国家，但随着我国社会人口老龄化的加剧以及生活方式的改变，
作者 韩邦旻
机构地区 上海交通大学附属第一人民医院泌尿外科
出处 《现代泌尿生殖肿瘤杂志》 2013年第3期186-188,共3页 Journal of Contemporary Urologic and Reproductive Oncology
关键词 辅助内分泌治疗 前列腺癌 应用 欧美国家 恶性肿瘤 人口老龄化 PCa 生活方式
分类号 R737.25 [医药卫生—肿瘤]
  • 相关文献

参考文献23

  • 1Baade PD, Youlden DR,Krnjacki LJ. International epidemi-ology of prostate cancer: geographical distribution and seculartrends[J], Mol Nutr Food Res,2009,53(2) : 171-184.
  • 22005年上海市恶性肿瘤发病率[J].上海预防医学,2008,20(8):421-422. 被引量：18
  • 3那彦群,孙则禹,叶章群,等.前列腺癌诊断治疗指南[M]//那彦群,叶章群,孙光.中国泌尿外科疾病诊断治疗指南.北京:人民卫生出版社,2011:30.
  • 4Labile F,Cusan L, Gomez JL, et al. Down-staging of early stageprostate cancer before radical prostatectomy: the first randomisedtrial of neoadjuvant combination therapy with flutamide and a lu-teinizing hormone-releasing agonist [j]. Urology,1994,44 (6 ):129-137.
  • 5Klotz LH,Goldenberg SL,Jewett MA, et al. Long-termfollowup of a randomized trial of 0 versus 3 months of neoad-juvant androgen ablation before radical prostatectomy [J]. JUrol,2003,170(3):791-794.
  • 6Soloway MS,Pareek K,Sharifi R,et al. Neoadjuvant andro-gen ablation before radical prostatectomy in cT2bNxM0 pros-tate cancerl S-year resuits[J]. J Urol,2002,167(1) :112-116.
  • 7Shelley MD, Kumar S,Wilt T,et al. A systematic reviewand meta-analysis of randomised trials of neoadjuvant hor-mone therapy for localised and locally advanced prostate car-cinoma[J]. Cancer Treat Rev,2009 ,35(1) : 9-17.
  • 8Pagliarulo V,Bracarda S,Eisenberger MA,et al. Contempo-rary role of androgen deprivation therapy for prostate cancer[J], Eur Urol,2012,61(1):11-25.
  • 9Blute ML,Bergstralh EJ,Iocca A,et al. Use of Gleason score,prostate specific antigen, seminal vesicle and margin status to pre-dict biochemical failure after radical prostatectomy[J]. J Urol,2001,165(1):119-125.
  • 10Cheng L,Zincke H,Blute ML, et al. Risk of prostate carci-noma death in patients with lymph node metastasis [ J].Cancer,2001,91(1):66-73.

共引文献17

同被引文献26

  • 1AndrOs E, Eschwege P, Lang H, et al. Metabolic impact of androgen deprivation therapy for prostate cancer[ J]. Prog Uro1,2012,22 ( Suppl 2) : $39-47.
  • 2Whitmore WF Jr. Hormone therapy in prostatic cancer[ J ]. The Ameri- can journal of medicine, 1956,21 (5) :697-713.
  • 3Klotz L, Boceon-Gibod L, Shore ND, et al. The efficacy and safety of degarelix a 12-month camparativer and omized open-label parallel- group phase nl study in patients with prostate cancer [ J]. BJU Int, 2008,102 ( 11 ) : 1531-1538.
  • 4de Bono JS, Logothetis C J, Molina A, et al. Abiraterone and increased survival in wctastatic prostate cancer [ J ]. N Engl J Med, 2011,364 (21) :1995-2005.
  • 5Agus DB, Stadler WM, Shevrin DH, et al. Safety, efficacy, and phar- macodynarnics of the investigational agent ortonel (TAK-700)in meta- static castration resistant prostate cancer (mCRPC):updated data from a phase 1 / II study[J]. J Clin Oncol,2012,30(5) :98.
  • 6Shen HC, Balk SP. Development of androgen receptor antagonists with promising activity in castration-resistant prostate cancer [ J ]. Cancer Ce11,2009,15(6) :461-463.
  • 7Labrie F. Hormonal therapy of prostate cancer [ J ]. Prog Brain Res, 2010,182(6) :321-341.
  • 8Pagliarulo V, Bracarda S,Eisenberger MA, et al. Contemporary role of androgen deprivation therapy for prostate cancer[ J]. Eur Uro1,2012, 61(1) :11-25.
  • 9Grossfeld GD, Chaudhary UB, Reese DM, et al. Intermittent androgen deprivation : update of cycling characteristics in patients without clinl- tally apparent metastatic prostate cancer[ J ]. Urology,2011,58 (2) : 240-245.
  • 10Klotz L. Intermittent versus continuous androgen deprivation therapy in advanced prostate cancer [ J ]. Curr Urol Rep, 2013,14 ( 3 ) : 159- 167.

引证文献2

二级引证文献11

现代泌尿生殖肿瘤杂志
2013年 第3期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部